GlassScriptPhysician profile
Katherine E Grimes
NPI 1023620457
$4,077.80
in general payments reported to CMS, 2019-2025
24 companies · $772 in 2025
The $772 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.60 · 2022: $491 · 2023: $1,754 · 2024: $1,045 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635 · Travel and Lodging: $883 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.78 |
| Travel and Lodging | $883.17 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,493.15 | 2023-2025 | Synchromedii, Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $730.31 | 2022-2025 | Belbuca, Xtampza |
| Nevro Corp. | $418.87 | 2022-2024 | Senza |
| Abbott Laboratories | $345.62 | 2024-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $326.77 | 2025 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.17 | 2022-2025 | Relistor |
| Painteq LLC | $103.05 | 2024 | Painteq |
| Teva Pharmaceuticals USA, INC. | $89.97 | 2022-2025 | Ajovy |
| Grt US Holding, INC. | $61.99 | 2021-2022 | |
| Vertos Medical, INC. | $61.04 | 2023-2024 | Mild Device Kit |
| Averitas Pharma INC. | $49.54 | 2023-2025 | Qutenza |
| Lilly USA, LLC | $46.07 | 2022 | |
| Lundbeck LLC | $26.35 | 2023 | Vyepti |
| Valinor Pharma, LLC | $24.05 | 2023 | Movantik |
| Abbvie INC. | $22.50 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $21.74 | 2025 | |
| Axonics, INC. | $21.00 | 2022 | |
| Fidia Pharma USA INC. | $20.81 | 2022 | |
| Protega Pharmaceutials INC | $19.24 | 2025 | Roxybond |
| Spr Therapeutics, INC | $19.15 | 2022 | |
| Foundation Fusion Solutions, LLC | $16.14 | 2024-2025 | |
| Nalu Medical, INC. | $15.70 | 2024 | Nalu Neurostimulation System |
| International Rehabilitative Sciences, INC | $14.34 | 2024 | Rs 4i Plus Sequential Stimulator |
| Stimwave Technologies Incorporated | $4.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Grimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.